Targeting CD33 in AML: Therapeutic Strategies With New Antibody–Drug Conjugates

In this educational activity with downloadable slides William Donnellan MD reviews key advances in CD33-targeted therapies for AML.

Share

Program Content

Activities

Targeting CD33 in AML
Targeting CD33 in AML: Therapeutic Strategies With New Antibody–Drug Conjugates
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 31, 2016

Expires: August 30, 2017

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Seagen